Davis R Ingram
Overview
Explore the profile of Davis R Ingram including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
1037
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grimm S, Karki M, Blum K, Bertocchio J, He R, Tripathi D, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39836407
Purpose: Renal medullary carcinoma (RMC) is a highly aggressive malignancy defined by the loss of the SMARCB1 tumor suppressor. It mainly affects young individuals of African descent with sickle cell...
2.
Beird H, Cloutier J, Gokgoz N, Eeles C, Griffin A, Ingram D, et al.
Lab Invest
. 2024 Oct;
104(11):102146.
PMID: 39357799
A solitary fibrous tumor (SFT) is a rare mesenchymal neoplasm that can arise at any anatomical site and is characterized by recurrent NAB2::STAT6 fusions and metastatic progression in 10% to...
3.
Lazcano R, Ingram D, Panse G, Lazar A, Wang W, Cloutier J
Hum Pathol
. 2024 Jul;
151:105632.
PMID: 39084565
Initially described as a highly specific immunohistochemical marker for carcinomas of mammary origin, trichorhinophalangeal syndrome type 1 (TRPS1) has subsequently been detected in a variety of other non-mammary tumors. In...
4.
Nakazawa M, Silverman I, Rimkunas V, Veloso A, Glodzik D, Johnson A, et al.
Mol Cancer Ther
. 2024 Apr;
23(7):1057-1065.
PMID: 38561019
Targeting the DNA damage response (DDR) pathway is an emerging therapeutic approach for leiomyosarcoma (LMS), and loss of RNase H2, a DDR pathway member, is a potentially actionable alteration for...
5.
Wangsiricharoen S, Ingram D, Morey R, Wani K, Lazar A, Wang W
Mod Pathol
. 2024 Jan;
37(3):100426.
PMID: 38219952
Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors that express smooth muscle and melanocytic makers. Diagnosis of PEComas can be challenging due to focal or lost expression of traditional...
6.
Goyal Y, Busch G, Pillai M, Li J, Boe R, Grody E, et al.
Nature
. 2023 Jul;
620(7974):651-659.
PMID: 37468627
Even among genetically identical cancer cells, resistance to therapy frequently emerges from a small subset of those cells. Molecular differences in rare individual cells in the initial population enable certain...
7.
Chu Y, Dai E, Li Y, Han G, Pei G, Ingram D, et al.
Nat Med
. 2023 May;
29(6):1550-1562.
PMID: 37248301
Tumor-infiltrating T cells offer a promising avenue for cancer treatment, yet their states remain to be fully characterized. Here we present a single-cell atlas of T cells from 308,048 transcriptomes...
8.
Nguyen T, Wang Y, Bui T, Lazcano R, Ingram D, Yi M, et al.
Cancer Res
. 2023 Jan;
83(6):939-955.
PMID: 36603130
Significance: An innovative sequential therapeutic strategy targeting Rb, followed by treatment with agents that perturb DNA synthesis pathways, results in synergistic killing of Rb-positive sarcomas that can be noninvasively monitored.
9.
Lazcano R, Barreto C, Salazar R, Carapeto F, Traweek R, Leung C, et al.
Front Oncol
. 2022 Oct;
12:1008484.
PMID: 36313661
Introduction: Undifferentiated pleomorphic sarcoma (UPS) can be associated with a relatively dense immune infiltration. Immune checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) are effective in 20% of UPS patients. We characterize...
10.
Cloutier J, Ingram D, Wani K, Lazar A, Wang W
Hum Pathol
. 2022 Sep;
130:88-94.
PMID: 36162599
Synovial sarcoma is an aggressive translocation-associated soft tissue tumor driven by an SS18-SSX fusion oncoprotein. TRPS1 is a recently identified marker for breast carcinoma, but less is known about its...